In a multicenter study of over 600 patients, researchers found that higher fecal hemoglobin levels and smoking increased the likelihood of needing a follow-up colonoscopy after capsule endoscopy.
The FDA has cleared IB-Stim as the first treatment specifically indicated for pediatric functional dyspepsia and related nausea, providing a noninvasive neuromodulation option for abdominal pain in patients aged 8 to 21 years.
The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.
A 3-year study found that most patients with moderate to severe ulcerative colitis who responded to initial upadacitinib treatment stayed in remission through 96 weeks, with manageable side effects and consistent results across dosage groups.